LANTERN PHARMA INC., 10-K filed on 3/27/2025
Annual Report
v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 17, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39318    
Entity Registrant Name Lantern Pharma Inc.    
Entity Central Index Key 0001763950    
Entity Tax Identification Number 46-3973463    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1920 McKinney Avenue    
Entity Address, Address Line Two 7th Floor    
Entity Address, City or Town Dallas    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 75201    
City Area Code (972)    
Local Phone Number 277-1136    
Title of 12(b) Security Common Stock, $0.0001 par value    
Trading Symbol LTRN    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period true    
Entity Shell Company false    
Entity Public Float     $ 44,285,965
Entity Common Stock, Shares Outstanding   10,784,725  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s definitive proxy statement for the registrant’s 2025 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the registrant’s year ended December 31, 2024 are incorporated herein by reference into Part III of this Annual Report on Form 10-K.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.0001    
Auditor Firm ID 274    
Auditor Name EisnerAmper LLP    
Auditor Location Philadelphia, Pennsylvania    
v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS    
Cash and cash equivalents $ 7,511,079 $ 21,937,749
Marketable securities 16,501,984 19,364,923
Prepaid expenses & other current assets 1,234,566 2,038,653
Total current assets 25,247,629 43,341,325
Property and equipment, net 47,440 52,127
Operating lease right-of-use assets 239,985 228,295
Other assets 36,738 25,869
TOTAL ASSETS 25,571,792 43,647,616
CURRENT LIABILITIES    
Accounts payable and accrued expenses 4,140,361 2,505,211
Operating lease liabilities, current 190,814 172,975
Total current liabilities 4,331,175 2,678,186
Operating lease liabilities, net of current portion 52,843 61,496
TOTAL LIABILITIES 4,384,018 2,739,682
COMMITMENTS AND CONTINGENCIES (NOTE 4)
STOCKHOLDERS’ EQUITY    
Preferred Stock (1,000,000 authorized at December 31, 2024 and December 31, 2023; $.0001 par value) (Zero shares issued and outstanding at December 31, 2024 and December 31, 2023)
Common Stock (25,000,000 authorized at December 31, 2024 and December 31, 2023; $.0001 par value) (10,784,725 shares issued and outstanding at December 31, 2024; 10,721,192 shares issued and outstanding at December 31, 2023) 1,078 1,072
Additional paid-in capital 97,058,323 96,258,726
Accumulated other comprehensive income (loss) 153,990 (107,460)
Accumulated deficit (76,025,617) (55,244,404)
Total stockholders’ equity 21,187,774 40,907,934
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 25,571,792 $ 43,647,616
v3.25.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, shares authorized 25,000,000 25,000,000
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares issued 10,784,725 10,721,192
Common stock, shares outstanding 10,784,725 10,721,192
v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
General and administrative $ 6,090,747 $ 5,983,255
Research and development 16,125,690 11,894,315
Total operating expenses 22,216,437 17,877,570
Loss from operations (22,216,437) (17,877,570)
Interest income 742,355 765,388
Other income, net 692,869 1,150,648
NET LOSS $ (20,781,213) $ (15,961,534)
Net loss per share of common shares, basic $ (1.93) $ (1.47)
Net loss per share of common shares, diluted $ (1.93) $ (1.47)
Weighted-average number of common shares outstanding, basic 10,762,319 10,842,365
Weighted-average number of common shares outstanding, diluted 10,762,319 10,842,365
v3.25.1
Consolidated Statements of Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
NET LOSS $ (20,781,213) $ (15,961,534)
Other comprehensive gain    
Unrealized gain on available-for-sale securities 115,761 282,252
Unrealized gain (loss) on foreign currency translation 145,689 (18,326)
Other comprehensive gain 261,450 263,926
Comprehensive loss $ (20,519,763) $ (15,697,608)
v3.25.1
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 1,086 $ 95,691,194 $ (371,386) $ (39,282,870) $ 56,038,024
Balance, shares at Dec. 31, 2022 10,857,040        
Issuance of restricted common stock awards $ 1 50,064 50,065
Issuance of restricted common stock awards, shares   12,000        
Cancellation of restricted common stock awards
Cancellation of restricted common stock awards, shares   (2,500)        
Share repurchase $ (15) (499,982) (499,997)
Share repurchases, shares   (145,348)        
Stock-based compensation 1,017,450 1,017,450
Net loss (15,961,534) (15,961,534)
Other comprehensive gain 263,926 263,926
Balance at Dec. 31, 2023 $ 1,072 96,258,726 (107,460) (55,244,404) 40,907,934
Balance, shares at Dec. 31, 2023 10,721,192        
Issuance of restricted common stock awards $ 2 80,798 80,800
Issuance of restricted common stock awards, shares   20,000        
Stock-based compensation 652,093 652,093
Net loss (20,781,213) (20,781,213)
Other comprehensive gain 261,450 261,450
Proceeds from warrant exercises $ 4 66,706 66,710
Proceeds from warrant exercises, shares   43,533        
Balance at Dec. 31, 2024 $ 1,078 $ 97,058,323 $ 153,990 $ (76,025,617) $ 21,187,774
Balance, shares at Dec. 31, 2024 10,784,725        
v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (20,781,213) $ (15,961,534)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 17,282 14,615
Accretion of investment discounts (238,574) (173,086)
Non-cash lease adjustments 173,211 160,228
Stock-based compensation 732,893 1,067,515
Foreign currency remeasurement loss 219,729 11,500
Realized (gain) loss on sale of marketable debt securities (9,065) 115,840
Unrealized gain on marketable equity securities (155,624) (119,650)
Changes in assets and liabilities:    
Operating lease liabilities (175,715) (159,255)
Prepaid expenses & other current assets 778,304 941,440
Accounts payable and accrued expenses 1,636,440 (236,181)
Other assets (10,869) (7,980)
Net cash flows used in operating activities (17,813,201) (14,346,548)
INVESTING ACTIVITIES    
Purchase of property and equipment (12,595) (18,734)
Purchase of marketable securities (17,275,680) (8,196,143)
Redemptions of marketable securities 20,657,643 7,284,667
Net cash flows provided by (used in) investing activities 3,369,368 (930,210)
FINANCING ACTIVITIES    
Proceeds from warrant and stock option exercises 66,710
Repurchases of shares including commissions (499,997)
Net cash flows provided by (used in) financing activities 66,710 (499,997)
Effect of foreign exchange rates on cash (49,547) (28,462)
CHANGE IN CASH AND CASH EQUIVALENTS FOR THE YEAR (14,426,670) (15,805,217)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 21,937,749 37,742,966
CASH AND CASH EQUIVALENTS, END OF YEAR 7,511,079 21,937,749
Non-cash investing and financing activities:    
Operating lease right-of-use asset acquired through operating lease liability 348,623 141,989
Remeasurement of operating lease right-of-use asset and operating lease liability 198,847
Removal of operating lease right-of-use assets and related operating lease liabilities upon early termination of leases $ 163,722
v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure [Table]    
Net Income (Loss) $ (20,781,213) $ (15,961,534)
v3.25.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Insider Trading Arrangements [Line Items]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Risk Management and Strategy. We employ processes for assessing, identifying, and managing material risks from cybersecurity threats that are incorporated into our overall risk management system. These items are designed to help protect our information assets from internal and external threats and protect the integrity and confidentiality of our data. Our system includes procedural and technical safeguards, response planning, and reviews of our policies. We engage various external entities, including consultants, to improve and enhance our cybersecurity processes and oversight. We provide employees and consultants with cybersecurity and prevention training including timely and relevant topics covering phishing, mobile security, and data protection and the need for reporting incidents and suspicious events immediately. 

Although we develop and maintain systems and controls designed to prevent cybersecurity threats from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage in more electronic transactions with service providers and relating to patients participating in clinical trials, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants’ efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.

 

As of the date of this report, we are not aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.

 
Cybersecurity Risk Management Processes Integrated [Text Block] We employ processes for assessing, identifying, and managing material risks from cybersecurity threats that are incorporated into our overall risk management system.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] As of the date of this report, we are not aware of any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.
Cybersecurity Risk Board of Directors Oversight [Text Block] Governance. Our senior management team conducts the regular assessment and management of material risks from cybersecurity threats, including review with our information technology team and third-party service providers. All employees and consultants are directed to report to our senior management any irregular or suspicious activity that could indicate a cybersecurity threat or incident. The Audit Committee of our Board of Directors evaluates our cybersecurity assessment and management policies, including quarterly discussions with our senior officers and independent registered accounting firm.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our senior management team conducts the regular assessment and management of material risks from cybersecurity threats, including review with our information technology team and third-party service providers.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.1
Organization, Principal Activities, and Basis of Presentation
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Principal Activities, and Basis of Presentation

Note 1. Organization, Principal Activities, and Basis of Presentation

 

Lantern Pharma Inc., and Subsidiaries (the “Company”) is an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s development portfolio includes three clinical stage oncology focused product candidates and consists of small molecule drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company’s A.I. platform, known as RADR®, uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company’s data-driven, genomically-targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates.

 

Lantern Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware on January 15, 2020. The Company’s principal operations are located in Texas. The Company formed a wholly owned subsidiary, Lantern Pharma Limited, in the United Kingdom in July 2017 and a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia in September 2021. In January 2023, the Company formed a wholly owned subsidiary, Starlight Therapeutics Inc. (“Starlight”), to continue with advancing the development of drug candidate LP-184’s central nervous system (CNS) and brain cancer indications.

 

Since inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection with preclinical studies, clinical trials and development of its RADR® platform. This now includes three lead drug candidates and an Antibody Drug Conjugate (ADC) program directed towards 11 disclosed therapeutic targets:

 

● LP-300 (Tavocept), which we are advancing in a Phase 2 clinical trial, the Harmonic™ trial, focused on never smokers with advanced non-small cell lung cancer;
   
● LP-184, which we are advancing in a Phase 1 clinical trial, and has potential for treatment of solid tumors including breast, pancreatic, bladder, and lung cancers, and glioblastoma and other CNS cancers. Following the formation of Starlight, the Company now refers to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”;
   
● LP-284, the stereoisomer (enantiomer) of LP-184, is advancing in a Phase 1 clinical trial, and has shown promising in-vitro and in vivo anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184; and
   
● Our ADC program is focused on developing highly specific ADCs with highly potent drug-payloads.

 

The Company’s fiscal year ends on December 31 of each calendar year. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations, and cash flows for each period presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates.

 

 

Any reference in these notes to applicable guidance refers to Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). To date, the Company has operated its business as one segment. The Company’s consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Lantern Pharma Limited, Starlight Therapeutics Inc. and Lantern Pharma Australia Pty Ltd. All intercompany balances and transactions have been eliminated in consolidation.

 
v3.25.1
Liquidity
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity

Note 2. Liquidity

 

The Company incurred a net loss of approximately $20,781,000 and $15,962,000 during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company had working capital of approximately $20,916,000.

 

The Company plans to continue to explore periodic capital raises and also plans to apply for grant funding in the future to assist in supporting its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of liquidity. We believe that our existing cash, cash equivalents, and marketable securities as of December 31, 2024, and our anticipated expenditures and capital commitments, will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing this Form 10-K for the year ended December 31, 2024.

 
v3.25.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.

 

Foreign Currency

 

We translate the financial statements of our Australian subsidiary, which has a functional currency of the Australian dollar, to U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for income and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Gains and losses resulting from foreign currency transactions that are denominated in currencies other than our functional currency (U.S. dollar) are included within other income, net on the consolidated statements of operations.

 

Risks and Uncertainties

 

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.

 

Our marketable securities may be impacted by various risks related to interest rates, market conditions and credit risk. Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at December 31, 2024 are in excess of FDIC coverage.

 

 

Research and Development

 

Research and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs for manufacturing and supplies, clinical site costs and other costs for the conduct of clinical trials, costs for technical infrastructure on the cloud for the purposes of developing the Company’s RADR® platform, and other costs for identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred.

 

Cash and Cash Equivalents

 

The Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash equivalents. Cash equivalents at December 31, 2024 and 2023 were approximately $6,619,000 and $20,881,000, respectively, and are included along with cash under the caption cash and cash equivalents on the Company’s consolidated balance sheets.

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets as of December 31, 2024 totaled approximately $1,235,000 and included approximately $820,000 of upfront payments for contractor fees, academic research studies and services, and subscriptions, approximately $318,000 of prepaid annual insurance fees, and approximately $97,000 of receivables from dividends and tax incentives.

 

Prepaid expenses and other current assets as of December 31, 2023 totaled approximately $2,039,000 and included approximately $746,000 of upfront payments for contractor fees, academic research studies and services, and subscriptions, approximately $125,000 of intellectual property related licensing and other fees, approximately $308,000 of prepaid annual insurance fees, and approximately $860,000 of receivables from interest and tax incentives.

 

 

Leases

 

The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities on our consolidated balance sheets. Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.

 

Marketable Securities

 

The Company’s marketable securities consist of government and agency securities, corporate bonds, mutual funds, and common stock. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance sheets.

 

Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and recorded as a separate component within accumulated other comprehensive income (loss) on the consolidated balance sheets until realized. Interest is reported within interest income on the consolidated statements of operations. We evaluate our available-for-sale debt securities to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference, if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in other income, net on the consolidated statements of operations, and any remaining unrealized losses are included in accumulated other comprehensive income (loss) on the consolidated balance sheets. The allowance for credit losses is zero at December 31, 2024 and 2023, and there were no credit losses recorded for the years ended December 31, 2024 and 2023.

 

Equity securities, which are composed of mutual funds and common stock, are recorded at fair value each reporting period, with changes in fair value of these investments, as well as dividends earned, recorded within other income, net on the consolidated statements of operations.

 

We determine realized gains and losses on the sale of marketable securities based on the specific identification method and record such gains and losses within other income, net on the consolidated statements of operations.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.

 

Stock-based Compensation

 

Stock-based awards have been accounted for as required by ASC 718 Compensation - Stock Compensation. Under ASC 718, awards are valued at fair value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they occur.

 

Recently Adopted Accounting Pronouncement

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. The Company adopted ASU 2023-07 during the year ended December 31, 2024. See Note 11 Segment Reporting for further details.

 

New Accounting Pronouncements Not Yet Adopted

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive and Income - Expense Disaggregation Disclosures (Subtopic 220-40), requiring public business entities to provide disaggregated disclosures of relevant income statement expenses. The amendments aim to improve financial reporting by enhancing transparency in the notes to financial statements, specifically regarding expense categories. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is assessing the effect of this update on its consolidated financial statements and related disclosures.

 

 

 
v3.25.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 4: Commitments and Contingencies

 

General

 

The Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research and development efforts. Significant agreements are described in detail below (collectively, the “License, Strategic Alliance, and Research Agreements”).

 

Set forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the years ended December 31, 2024 and 2023, respectively. These expensed amounts are included under research and development expenses in the accompanying consolidated statements of operations.

 

         
   Year Ended 
   December 31, 
   2024   2023 
         
Amount Expensed for License, Strategic Alliance, and Research Agreements  $6,882,000   $5,993,000 

 

 

Set forth below at December 31, 2024 and 2023, respectively, are (1) the approximate amounts accrued and payable under the License, Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under the License, Strategic Alliance, and Research Agreements. These amounts are included in the accompanying consolidated balance sheets at December 31, 2024 and 2023.

 

   2024   2023 
         
Amount accrued and payable under License, Strategic Alliance, and Research Agreements  $1,725,000   $1,563,000 
           
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements  $490,000   $511,000 

 

BioNumerik Pharmaceuticals

 

In January 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with BioNumerik Pharmaceuticals, Inc. (“BioNumerik”), pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling $25,000 in connection with entry into the Assignment Agreement.

 

In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion. The Company has the right to first recover certain designated portions of patent costs and development and regulatory costs before the payment of royalties described above.

 

If the Company enters into a third-party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from such third-party transaction.

 

In addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make specified regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that the Company will provide TriviumVet DAC (“TriviumVet”) with (i) specified data and information generated by the Company with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications.

 

The Company is also required to pay all patent costs on covered patents related to LP-300. These patent costs are included in general and administrative expenses in the accompanying consolidated statements of operations. These patent costs are fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment of patent costs until such costs are fully recovered.

 

 

In addition to the recovery of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior to making any royalty or third-party transaction sharing payments. The Company also has the right to recover previously incurred LP-300 development and regulatory costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of development and regulatory costs until such costs are fully recovered. No amounts were expensed with respect to BioNumerik during the years ended December 31, 2024 and 2023, respectively.

 

AF Chemicals

 

In January 2015, the Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals, LLC (“AF Chemicals”) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February 2016, the Company and AF Chemicals entered into an Addendum (the “Addendum”) providing for additions and amendments to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the “Second Addendum”) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement, Addendum and Second Addendum are collectively referred to as the “AFC License Agreement”.

 

Pursuant to the Second Addendum, the Company made specified payments to AF Chemicals during the twelve months ended December 31, 2024. The Second Addendum also provides that, from December 30, 2020 until January 15, 2025, the Company will have no obligation to pay annual licensing fees, development diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.

 

As part of the Second Addendum, the Company has agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also amends and clarifies other provisions of the Technology License Agreement, and provides the Company with the ability to recover a portion of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by the Company or third parties prior to January 15, 2025.

 

Pursuant to the AFC License Agreement the Company made annual licensing fee payments to AF Chemicals relating to LP-184 for periods prior to signing the Second Addendum. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application (“IND”) filing relating to LP-184 or LP-284 and also upon reaching additional specified milestones in connection with the development and potential marketing approval of LP-184 or LP-284 in the United States, specified countries in Europe, and other countries.

 

The AFC License Agreement also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net sales of LP-184, LP-284 and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals.

 

Pursuant to the Second Addendum, no additional payments of annual licensing fees or development diligence extension payments related to LP-184 or LP-284 were required to be made by the Company until January 15, 2025, at which time these obligations have resumed. The Company is also obligated to make payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below.

 

In the event of a sublicense of the LP-184 or LP-284 rights to a non-affiliated party, the Company is obligated to pay AF Chemicals (a) a low double-digit percentage of the gross income and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.

 

 

The amounts to be paid to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to be paid with respect to LP-184 as described above. In addition, the AFC License Agreement contains specified time requirements for the Company to enroll patients in clinical trials and file a potential NDA with respect to LP-100. Extension fees may be paid by the Company to AF Chemicals from time to time related to these requirements. Pursuant to the Second Addendum with AF Chemicals, no additional payments of annual licensing fees or development diligence extension payments were required to be made by the Company with respect to LP-100 until January 15, 2025, at which time these obligations have resumed. Approximately $125,000 and $175,000 were expensed with respect to the AFC License Agreement during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations.

 

Allarity Therapeutics (formerly known as Oncology Venture)

 

In May 2015, the Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License and Development Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing for additions and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement, as amended (collectively, the “Allarity License and Development Agreement”), Allarity Therapeutics agreed to directly pay to AF Chemicals on behalf of the Company certain amounts to satisfy the Company’s milestone obligations to AF Chemicals with respect to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the Company would then be deducted from amounts owed by Allarity Therapeutics to the Company.

 

On July 23, 2021, the Company entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity. The transaction includes global rights to LP-100, as well as the developed clinical protocol for an intended study in bladder and prostate cancer patients who have a mutation in the ERCC2/3 genes. As a result of this transaction, the Company has full authority to manage and guide future clinical development and commercialization of LP-100. Under the terms of the Asset Purchase Agreement, the Company paid an initial upfront payment of $1,000,000 to Allarity, with an additional $1,000,000 held in escrow, which were subsequently released to the Company, with the final release occurring in August 2023. The Company determined there was no planned alternative future use for these assets outside of the clinical development of LP-100 and therefore the full amount of the upfront payment was included in research and development expense. Allarity is also eligible to receive additional milestone payments over the life of the program based on IP license milestones and regulatory filings and approvals in the US and EU, and low- to mid-single-digit royalties on future commercial net sales.

 

Fortrea Inc.

 

In May 2023, the Company entered into initial agreements with Fortrea Inc. (“Fortrea”) to begin serving as the lead contract research organization (CRO) for the Company’s Phase 2 clinical trial for LP-300 and the Company’s Phase 1 clinical trial for LP-184. In July 2023, the Company entered into a clinical master services agreement and work orders with Fortrea regarding additional CRO services to be provided by Fortrea relating to the LP-300 Phase 2 trial and the LP-184 Phase 1 trial. In October 2023, the Company entered into a start-up work order with Fortrea regarding start-up assistance services to be provided by Fortrea relating to the LP-284 Phase 1 trial, which start-up work order terminated in the first quarter of 2024. The Company and Fortrea entered into a modification of the work order for the LP-184 Phase 1 trial effective December 2024, which modification provided for the transition from Fortrea to the Company of all work conducted by Fortrea relating to the LP-184 Phase 1 trial. The Company is currently discussing with Fortrea a potential amendment to make certain adjustments to the work order with Fortrea relating to the LP-300 Phase 2 clinical trial. The Company expects to finalize and enter into the amendment to the LP-300 work order in the second quarter of 2025. Approximately $5,487,000 and $2,096,000 was expensed with respect to the Fortrea agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects to make substantial payments to Fortrea over the next 12 to 18 months in connection with services provided by Fortrea as well as clinical trial site and other pass-through costs relating to the LP-300 Phase 2 trial.

 

Patheon API Services

 

The Company has entered into agreements with Patheon API Services, Inc. (“Patheon”) for the manufacture and supply of cGMP material to support the Company’s Phase 2 clinical trial for its product candidate LP-300. In addition to producing LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon transferred previously validated manufacturing processes and analytical methods for LP-300 and produced non-GMP material for use in support of non-clinical studies for LP-300. The agreements provided for payments in stages as specified process and manufacturing milestones are achieved. Approximately $18,000 and $4,000 was expensed with respect to the Patheon agreements during the years ended December 31, 2024 and 2023, respectively. These expenses were reduced by approximately $30,000 and $35,000 during the years ended December 31, 2024 and 2023, respectively, due to a reduction in accrual estimates. These amounts for the years ended December 31, 2023 and 2024 are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects to expense additional amounts in future periods in accordance with the progress of work completed under the Patheon agreements.

 

 

Piramal Pharma Solutions

 

In January 2021, the Company entered into an agreement with Piramal Pharma Solutions (“Piramal”) for the fill and finish manufacture of LP-300 drug product at Piramal’s Lexington, Kentucky site in support of future Phase 2 clinical testing. The agreement, as amended, and additional agreements entered into with Piramal have provided for Piramal to conduct activities in support of the cGMP manufacturing of LP-300, including analytical and process transfer activities, manufacture of cGMP clinical batches, and performance of stability studies on cGMP batches of LP-300 drug product. Approximately $130,000 and $49,000 was expensed with respect to Piramal agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects to expense additional amounts in future periods with respect to Piramal relating to stability studies and analytical support activities.

 

vivoPharm

 

In September 2021, the Company’s Australian subsidiary entered into an agreement with RDDT, a vivoPharm Company Pty Ltd (“vivoPharm”), for multiple preclinical studies, including animal studies, as part of an IND-enabling program for LP-184. The Company’s Australian subsidiary entered into an additional agreement with vivoPharm in 2022 as part of an IND-enabling program for LP-284. Amendments to the vivoPharm agreements were made in 2022 and 2023, and additional agreements were entered into with vivoPharm in 2023 and 2024 relating to preclinical studies and related data analysis and support work. Approximately $56,000 and $1,012,000 was expensed with respect to the vivoPharm agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations.

 

TD2

 

In October 2021, the Company entered into a Statement of Work, as amended in March 2022, with Translational Drug Development, LLC (“TD2”) providing for TD2 to serve as the lead contract research organization (CRO) for the Company’s Phase 2 clinical trial for its product candidate LP-300. No amounts were expensed during the year ended December 31, 2024 and approximately $420,000 was expensed with respect to TD2 during the year ended December 31,2023, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company’s agreements with TD2 were terminated in 2023 in connection with the Company’s engagement of Fortrea to provide contract research organization services to the Company.

 

Berkshire Sterile Manufacturing

 

During the years ended December 31, 2023 and 2024, the Company entered into agreements with Berkshire Sterile Manufacturing (“Berkshire”) to support technical transfer and GMP drug product manufacturing of LP-300. Approximately $141,000 and $334,000 were expensed with respect to the Berkshire agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects that additional amounts will be expensed in future periods in accordance with the progress of work completed under the Berkshire agreements.

 

 

Shilpa

 

In March 2022, the Company entered into an agreement with Shilpa Medicare Limited (“Shilpa”) for fit-to-purpose process development and synthesis of a key starting material relating to the synthesis of LP-184 under cGMP. In July 2022, the Company entered into agreements with Shilpa Pharma Lifesciences for the cGMP synthesis of LP-184 API material as well as for drug product development and cGMP drug product manufacturing of LP-184. In August 2022, the Company entered into agreements with Shilpa for the cGMP synthesis of LP-284 API material as well as for drug product development and cGMP drug product manufacturing of LP-284. The Company entered into additional agreements with Shilpa and its subsidiaries and affiliates in 2023 and in 2024 to support cGMP drug substance and drug product manufacturing and stability studies for LP-184 and LP-284. Approximately $827,000 and $1,313,000 were expensed with respect to the Shilpa agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects that additional amounts will be expensed in future periods in accordance with the progress of work completed under the Shilpa agreements.

 

Curia

 

During the years ended December 31, 2023 and 2024, the Company entered into agreements with Curia Global, Inc. (“Curia”) relating to the cGMP manufacture of LP-300 API and supporting activities. Approximately $82,000 and $414,000 were expensed with respect to the Curia agreements during the years ended December 31, 2024 and 2023, respectively, which amounts are included in research and development expenses in the accompanying consolidated statements of operations. The Company expects that additional amounts will be expensed in future periods in accordance with the progress of work completed under the Curia agreements.

 

LumaBridge (formerly known as Cancer Insight)

 

In May 2022, the Company entered into an agreement with Cancer Insight, LLC, now known as LumaBridge, LLC (“LumaBridge”) for IND filing, regulatory support, Phase 1 pre-trial startup activities, and strategic program consulting relating to LP-184. No amounts were expensed during the year ended December 31, 2024 and approximately $200,000 was expensed with respect to the LumaBridge agreements during the year ended December 31, 2023 which amounts are included in research and development expenses in the accompanying consolidated statements of operations.

 

Other Research and Service Provider Agreements

 

In addition to the agreements described above, the Company has entered into other research and service provider agreements for the advancement of its product candidates and research and development efforts. The Company expects to expense additional amounts in future periods in connection with existing and future research and service provider agreements.

 

 

Actuate Therapeutics

 

In May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (“Actuate”), a clinical stage private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis. Pursuant to the agreement, the Company and Actuate have collaborated on utilization of the Company’s RADR® platform to develop novel biomarker derived signatures for use with one of Actuate’s product candidates. As part of the collaboration, the Company received 25,000 restricted shares of Actuate stock, subject to meeting certain conditions of the collaboration, as well as the potential to receive additional Actuate stock if results from the collaboration are utilized in future development efforts. In 2023, the term of the Collaboration Agreement was extended until March 31, 2024. The Company is currently evaluating the possibility of further collaborations with Actuate. Certain affiliates of Bios Partners beneficially own greater than 10% of the Company’s common stock and also hold substantial beneficial ownership interests in Actuate. Through December 31, 2024, no revenues have been recognized under the Agreement.

 

The restricted shares of Actuate stock had a nominal value when acquired and, therefore, were recorded at a cost of $0. In August 2024, Actuate announced the closing of its initial public offering (“IPO”), which also included a reverse stock split. Following the reverse stock split and the IPO, the Company holds 13,889 shares of common stock, which can be sold by the Company without restriction in accordance with Rule 144 of the Securities Act of 1933. At December 31, 2024, the Actuate common stock held by the Company had a fair value of approximately $111,000, which was reported as an unrealized gain in other income, net on the Company’s condensed consolidated statements of operations for the year ended December 31, 2024.

 
v3.25.1
Leases
 12 Months Ended
Dec. 31, 2024
Leases  
Leases

Note 5. Leases

 

The following provides balance sheet information related to leases as of December 31, 2024 and 2023:

 

    2024     2023  
Assets                
Operating lease, right-of-use asset, net   $ 239,985     $ 228,295  
Liabilities                
Current portion of operating lease liabilities   $ 190,814     $ 172,975  
Operating lease liabilities, net of current portion     52,843       61,496  
Total operating lease liabilities   $ 243,657     $ 234,471  

 

 

At December 31, 2024, the future estimated minimum lease payments under non-cancelable operating leases are as follows:

 

     
2025  $205,315 
2026   54,744 
Total minimum lease payments   260,059 
Less amount representing interest   (16,402)
Present value of future minimum lease payments   243,657 
Less current portion of operating lease liabilities   (190,814)
Operating lease liabilities, net of current portion  $52,843 

 

The Company leases office space in the Dallas, Texas and Atlanta, Georgia metropolitan areas under non-cancellable operating leases. In January 2023, the Company renewed its existing lease in the Atlanta area for an additional two years (“Colony Square Lease”). Effective August 31, 2024, the Colony Square Lease was terminated in conjunction with a new lease with the same landlord. The new lease began September 1, 2024 for a period of 24 months, requires payments of approximately $6,800 per month, and is subject to automatic renewal on a month-to-month basis unless the Company provides three-months written notice to the landlord. The exercise of lease renewal options is at the Company’s sole discretion and is assessed as to whether to include any renewals in the lease term at inception.

 

In January 2023, the Company also entered into two new leases in Dallas that commenced in March 2023 and May 2023, respectively (“Legacy West Leases”). Effective April 30, 2024, the Legacy West Leases were terminated in conjunction with a new lease with the same landlord. The new lease began May 1, 2024 for a period of 19 months, requires payments of approximately $11,200 per month, and is subject to automatic renewal on a month-to-month basis unless the Company provides three-months written notice to the landlord. The exercise of lease renewal options is at the Company’s sole discretion and is assessed as to whether to include any renewals in the lease term at inception.

 

The following table provides a reconciliation for the Company’s right of use assets and lease liabilities:

 

   Right-of-Use Asset   Operating Lease Liability 
Balance at January 1, 2023  $47,687   $52,890 
Remeasurement of operating lease right-of-use assets and operating lease liability   198,847    198,847 
Operating right-of-use asset acquired through operating lease liability   141,989    141,989 
Amortizations   (160,228)   (159,255)
Balance at December 31, 2023   228,295    234,471 
Early termination of operating leases   (163,722)   (163,722)
Operating right-of-use asset acquired through operating lease liability   348,623    348,623 
Amortizations   (173,211)   (175,715)
Balance at December 31, 2024  $239,985   $243,657 

 

Other supplemental information related to operating leases is as follows:

 

         
  

As of

December 31,

 
   2024   2023 
Weighted average remaining term of operating leases (in years)   1.30    1.33 
Weighted average discount rate of operating leases   9.50%   7.36%

 

The Company also leased office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2024 and 2023. In April 2023, the Company entered into a two-year lease for material storage and handling. The lease is cancellable with 45-days’ written notice. Under these short-term leases, the Company elected the short-term lease measurement and recognition exemption under ASC 842 and recorded rent expense as incurred.

 

The components of lease expense were approximately as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
Operating lease cost  $191,000   $178,000 
Short-term lease cost   19,000    14,000 
Lease expense  $210,000   $192,000 

 

During the years ended December 31, 2024 and 2023, cash used in operating activities associated with these leases was approximately $194,000 and $177,000, respectively.

 
v3.25.1
Shareholders’ Equity
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Shareholders’ Equity

Note 6. Shareholders’ Equity

 

Preferred Stock

 

Upon the Company’s IPO, all shares of the Company’s Series A preferred stock were converted into 2,438,851 shares of common stock effective June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December 31, 2024 and 2023, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.

 

 

Common Stock

 

During the year ended December 31, 2023, the Company repurchased 145,348 shares of its common stock for an aggregate purchase price of approximately $500,000. Upon purchase, the repurchased shares ceased to be outstanding and returned to the status of authorized and unissued shares of common stock.

 

During the year ended December 31, 2023, the Company issued 12,000 shares of restricted common stock to consultants with a grant date fair value of approximately $63,000. 9,500 shares of restricted stock vested during 2023, and the remaining 2,500 were forfeited. The Company reported approximately $50,000 of stock-based compensation related to the vested restricted common stock during the year ended December 31, 2023, which is included in general and administrative expenses in the accompanying consolidated statements of operations. With the vesting of the 9,500 shares of restricted stock as described above, no shares of restricted common stock were outstanding at December 31, 2023.

 

During the year ended December 31, 2024, the Company issued 20,000 shares of restricted common stock to a consultant with a grant date fair value of approximately $81,000, which was included as stock-based compensation as part of general and administrative expenses in the accompanying consolidated statements of operations when the shares vested on October 4, 2024. No shares of restricted common stock were outstanding at December 31, 2024.

 

As of December 31, 2024 and December 31, 2023, the Company had 25,000,000 authorized shares of Common Stock, of which 10,784,725 and 10,721,192 shares were issued and outstanding, respectively.

 

Warrants

 

The Company had warrants to purchase 177,998 shares of common stock outstanding and exercisable as of December 31, 2023 at a weighted average exercise price of $9.27 per share, and with expiration dates ranging from March 7, 2024 to June 10, 2025.

 

During the year ended December 31, 2024, the Company issued 21,313 shares of common stock for aggregate proceeds of $66,710, relating to the exercise of warrants that were expiring. The Company also issued 22,220 shares of common stock relating to the cashless exercise of warrants to purchase 86,685 shares during the year ended December 31, 2024. The Company had warrants to purchase 70,000 shares of common stock outstanding and exercisable as of December 31, 2024 at a weighted average exercise price of $18.75 per share, which warrants expire on June 10, 2025.

 

Options

 

On August 29, 2018, the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was subsequently amended on December 17, 2018, February 26, 2020, October 20, 2022, June 16, 2023 and June 13, 2024. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated, is referred to herein as the “Plan”. The Company has reserved 1,864,680 shares of its common stock for issuance under the Plan. The Plan is designed to provide additional incentives to employees, directors and consultants to remain in the service of the Company as well as to encourage stock acquisition by members of these targeted groups, which in the opinion of the management will support the alignment of the interests of the members of these groups and stockholders. Options granted under the Plan are generally exercisable for up to 10 years from grant date. 423,693 shares remain available for future awards under the Plan at December 31, 2024, following the grant of options and the award of restricted stock grants through December 31, 2024.

 

 

A summary of stock option activity under the Plan during the years ended December 31, 2024 and 2023 is presented below:

 

   Options Outstanding   Options Exercisable 
  

Number of

Shares

  

Weighted-Average

Exercise Price

  

Number of

Options

  

Weighted-Average

Exercise Price

 
Outstanding December 31, 2022   1,037,591   $6.46    755,073   $5.87 
Granted   126,000    4.43           
Cancelled or expired   (72,395)   8.20           
Outstanding December 31, 2023   1,091,196    6.11    880,241    6.25 
Granted   259,000    4.56           
Cancelled or expired   (104,502)   6.90           
Outstanding December 31, 2024   1,245,694   $5.72    971,472   $6.07 

 

The weighted average remaining contractual term of outstanding options at December 31, 2024 is 6.14 years. The weighted average remaining contractual term of exercisable options at December 31, 2024 is 5.27 years. The total intrinsic value of options outstanding at December 31, 2024 and 2023 was approximately $1,014,000 and $1,552,000, respectively. The total intrinsic value of options exercisable at December 31, 2024 and 2023, was approximately $1,014,000 and $1,526,000, respectively.

 

Approximate stock-based compensation relating to options was as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
General and administrative  $291,000   $566,000 
Research and development   361,000    451,000 
Stock-based compensation  $652,000   $1,017,000 

 

Total remaining unrecognized compensation expense for non-vested options is approximately $908,000 as of December 31, 2024, and is expected to be recognized over a weighted average period of 1.54 years.

 

For the years ended December 31, 2024 and 2023, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following weighted average assumptions:

 

   2024   2023 
Term (in years)   5.58    5.73 
Risk Free Rate   4.15%   4.01%
Volatility   88.35%   86.91%
Dividend Yield   0.00%   0.00%
           
Grant Date Fair Value  $3.36   $3.25 

 

The fair value of options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.

 

Expected Term - The Company used a weighted average of time to vesting and maturity date.
Expected Volatility- Due to the Company’s limited operating history and a lack of company-specific historical and implied volatility data, the Company has in part based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded commensurate with expected term as of grant date. The historical volatility data was computed using the daily closing prices for the selected comparable companies’ shares.
Risk-Free Interest Rate- The Company used the U.S. treasury bill rate commensurate with the expected term as of grant date.
Expected Dividend- As the Company has not issued any dividends and does not expect to issue dividends over the life of the options, the Company has estimated the dividend yield to be zero.

 

 
v3.25.1
Securities
 12 Months Ended
Dec. 31, 2024
Cash and Cash Equivalents [Abstract]  
Securities

Note 7. Securities

 

At December 31, 2024, the Company’s debt and equity securities, including approximately $2,542,000 classified in cash and cash equivalents, consisted of the following:

 

  

Amortized

Cost

  

Unrealized

Gains

  

Unrealized

Losses

  

Aggregate

Fair Value

 
Government and agency securities  $11,461,885   $3,270   $(1,670)  $11,463,485 
Corporate bonds   1,845,226    953    (944)   1,845,235 
Debt securities  $13,307,111   $4,223   $(2,614)   13,308,720 
Equity securities                  6,429,576 
                  $19,738,296 
                     
Included in cash and cash equivalents                 $3,236,312 
Included in marketable securities                 $16,501,984 

 

At December 31, 2023, the Company’s debt and equity securities consisted of the following:

 

  

Amortized

Cost

  

Unrealized

Gains

  

Unrealized

Losses

  

Aggregate

Fair Value

 
Government and agency securities  $5,576,819   $3,969   $(66,680)  $5,514,108 
Corporate bonds   8,322,723    514    (44,872)   8,278,365 
Debt securities  $13,899,542   $4,483   $(111,552)   13,792,473 
Equity securities                  15,825,016 
                  $29,617,489 
                     
Included in cash and cash equivalents                 $10,252,566 
Included in marketable securities                 $19,364,923 

 

The contractual maturities of the Company’s debt securities, including approximately $2,542,000 classified in cash and cash equivalents, are as follows:

 

  

As of

December 31, 2024

 
Due within one year  $13,308,720 

 

 

The following table presents gross unrealized losses and fair values for those marketable debt securities that were in an unrealized loss position as of December 31, 2024, aggregated by investment category and the length of time that individual debt securities have been in a continuous loss position:

 

                 
   As of
December 31, 2024		 
   Less than 12 months   More than 12 months 
  

Fair

Value

  

Unrealized

Loss

  

Fair

Value

  

Unrealized

Loss

 
Government and agency securities  $1,284,465   $(64)  $797,324   $(1,606)
Corporate bonds   -    -    297,687    (944)
   $1,284,465   $(64)  $1,095,011   $(2,550)

 

We do not believe the unrealized losses on debt securities represent credit losses based on our evaluation of available evidence as of December 31, 2024, which includes an assessment of whether it is more likely than not we will be required to sell the investment before recovery of the investment’s amortized cost basis.

 
v3.25.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 8. Fair Value Measurements

 

We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

 

Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

 

Level 3 - Inputs are unobservable inputs based on our assumptions.

 

Financial Assets

 

When available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker reports that utilize quoted market prices for comparable instruments. As of December 31, 2024 and 2023 our available-for-sale debt securities were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our money market accounts, common stock and mutual funds were valued using quoted prices in active markets for identical assets and are classified as Level 1.

 

Based on our valuation of our marketable securities, we concluded that they are classified in either Level 1 or Level 2, and we have no financial assets measured using Level 3 inputs. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories.

 

                 
  

Fair Value Measurements as of

December 31, 2024

 
Description  Total   Level 1   Level 2   Level 3 
Government and agency securities  $11,463,485   $-   $11,463,485   $- 
Corporate bonds   1,845,235    -    1,845,235    - 
Money markets   694,420    694,420    -    - 
Mutual funds – fixed income   3,777,950    3,777,950    -    - 
Mutual funds – alternative investments   1,846,650    1,846,650    -    - 
Common stock   110,556    110,556    -    - 
Fair value recurring basis  $19,738,296   $6,429,576   $13,308,720   $- 
                     
Included in cash and cash equivalents  $3,236,312                
Included in marketable securities  $16,501,984                

 

                 
  

Fair Value Measurements as of

December 31, 2023

 
Description  Total   Level 1   Level 2   Level 3 
Government and agency securities  $5,514,108   $-   $5,514,108   $- 
Corporate bonds   8,278,365    -    8,278,365    - 
Money markets   10,252,566    10,252,566    -    - 
Mutual funds – fixed income   3,733,600    3,733,600    -    - 
Mutual funds – alternative investments   1,838,850    1,838,850    -    - 
Fair value recurring basis  $29,617,489   $15,825,016   $13,792,473   $- 
                     
Included in cash and cash equivalents  $10,252,566                
Included in marketable securities  $19,364,923                

 
v3.25.1
Loss Per Share of Common Shares
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Loss Per Share of Common Shares

Note 9. Loss Per Share of Common Shares

 

Basic loss per share is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due to being anti-dilutive include the following:

 

         
  

For the year ended

December 31,

 
   2024   2023 
Warrants   70,000    177,998 
Stock options   1,245,694    1,091,196 
Anti-dilutive securities   1,315,694    1,269,194 

 

 
v3.25.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

Note 10. Income Taxes

 

Our effective tax rate differs from the statutory federal tax rate as presented in the following table:

 

   2024   2023 
U.S. federal statutory tax rate   21%   21%
Permanent differences   4%   -%
Valuation allowance   (25)%   (21)%
           
Total:   -%   -%

 

As of December 31, 2024 and 2023, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no current federal or state tax.

 

The tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented below.

 

         
   December 31, 
   2024   2023 
Deferred tax assets          
Research and development credits  $2,222,625   $1,436,914 
Stock-based compensation   584,840    538,771 
Net operating loss carryforwards   9,353,936    7,383,777 
Unrealized losses on securities   -    22,624 
Research and development amortization   5,617,727    3,164,305 
Deferred tax asset   17,779,128    12,546,391 
           
Less: valuation allowance   (17,772,997)   (12,542,542)
Net deferred tax asset   6,131    3,849 
           
Deferred tax liabilities          
Unrealized gains on securities   (1,837)   - 
Operating lease right-of-use assets   (776)   - 
Fixed assets   (3,518)   (3,849)
Net deferred tax assets  $-   $- 

 

Due to a history of losses the Company has generated since inception, the Company believes it is more-likely-than-not that all of the deferred tax assets will not be realized as of December 31, 2024 and 2023. Therefore, the Company has recorded a full valuation allowance on its deferred tax assets. At December 31, 2024 and 2023, the Company has net operating loss (“NOL”) carryforwards for federal income tax purposes of approximately $43,600,000 and $34,500,000, respectively. The NOL carryforwards generated prior to 2018 of approximately $3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated from January 1, 2018 through December 31, 2024 of approximately $40,500,000 do not expire and are carried forward indefinitely. The Company has state NOLs of approximately $1,000,000 at December 31, 2024. Australian NOLs were approximately $500,000 at December 31, 2024 and can be carried forward indefinitely, but may be subject to limitation in the event of certain corporate stock transactions the Company may enter into in the future. The Company also has approximately $2,200,000 of research and development tax credit carryforwards for federal purposes. These credits begin expiring in 2039. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s NOL carryforwards and research and development credit carryforwards may be subject to annual limitations under Section 382 of the Internal Revenue Code against taxable income in the future period, which could substantially limit the eventual utilization of such carryforwards.

 

Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain positions. In addition, interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there were none. The Company’s U.S. federal operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The statute of limitations expires three years after the utilization of historical losses.

 

The Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities and amortize over five years for U.S. activities and 15 years for non-U.S. activities using a mid-year convention. Therefore, the capitalization of research and development costs in accordance with IRC 174 resulted in a net deferred tax asset of $5,617,727 as of December 31, 2024.

 
v3.25.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting

Note 11: Segment Reporting

 

The Company operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its chief executive officer, who reviews financial information presented on a consolidated basis. The CODM uses expected research and development study and material costs; cash, cash equivalents and marketable securities balances; operating losses; and budget projections to assess financial performance and allocate resources. During the years ended December 31, 2024 and 2023, research and development study and material costs, which include clinical trial and product candidate manufacturing costs, were approximately $11,400,000 and $8,453,000, respectively. These financial metrics are used by the CODM to make key operating decisions, such as which research and development studies to commence, extend or discontinue. See the consolidated balance sheets and statements of operations as of and for the years ended December 31, 2024 and 2023.
v3.25.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.

 
Foreign Currency

Foreign Currency

 

We translate the financial statements of our Australian subsidiary, which has a functional currency of the Australian dollar, to U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for income and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Gains and losses resulting from foreign currency transactions that are denominated in currencies other than our functional currency (U.S. dollar) are included within other income, net on the consolidated statements of operations.

 
Risks and Uncertainties

Risks and Uncertainties

 

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.

 

Our marketable securities may be impacted by various risks related to interest rates, market conditions and credit risk. Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at December 31, 2024 are in excess of FDIC coverage.

 

 
Research and Development

Research and Development

 

Research and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs for manufacturing and supplies, clinical site costs and other costs for the conduct of clinical trials, costs for technical infrastructure on the cloud for the purposes of developing the Company’s RADR® platform, and other costs for identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers money market funds and other highly liquid instruments with a short-term maturity of 3 months or less to be cash equivalents. Cash equivalents at December 31, 2024 and 2023 were approximately $6,619,000 and $20,881,000, respectively, and are included along with cash under the caption cash and cash equivalents on the Company’s consolidated balance sheets.

 
Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets as of December 31, 2024 totaled approximately $1,235,000 and included approximately $820,000 of upfront payments for contractor fees, academic research studies and services, and subscriptions, approximately $318,000 of prepaid annual insurance fees, and approximately $97,000 of receivables from dividends and tax incentives.

 

Prepaid expenses and other current assets as of December 31, 2023 totaled approximately $2,039,000 and included approximately $746,000 of upfront payments for contractor fees, academic research studies and services, and subscriptions, approximately $125,000 of intellectual property related licensing and other fees, approximately $308,000 of prepaid annual insurance fees, and approximately $860,000 of receivables from interest and tax incentives.

 

 
Leases

Leases

 

The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities on our consolidated balance sheets. Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.

 
Marketable Securities

Marketable Securities

 

The Company’s marketable securities consist of government and agency securities, corporate bonds, mutual funds, and common stock. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond twelve months, as current assets in the accompanying consolidated balance sheets.

 

Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and recorded as a separate component within accumulated other comprehensive income (loss) on the consolidated balance sheets until realized. Interest is reported within interest income on the consolidated statements of operations. We evaluate our available-for-sale debt securities to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference, if any, is caused by expected credit losses. Allowance for credit losses are recognized as a charge in other income, net on the consolidated statements of operations, and any remaining unrealized losses are included in accumulated other comprehensive income (loss) on the consolidated balance sheets. The allowance for credit losses is zero at December 31, 2024 and 2023, and there were no credit losses recorded for the years ended December 31, 2024 and 2023.

 

Equity securities, which are composed of mutual funds and common stock, are recorded at fair value each reporting period, with changes in fair value of these investments, as well as dividends earned, recorded within other income, net on the consolidated statements of operations.

 

We determine realized gains and losses on the sale of marketable securities based on the specific identification method and record such gains and losses within other income, net on the consolidated statements of operations.

 
Income Taxes

Income Taxes

 

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.

 
Stock-based Compensation

Stock-based Compensation

 

Stock-based awards have been accounted for as required by ASC 718 Compensation - Stock Compensation. Under ASC 718, awards are valued at fair value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they occur.

 
Recently Adopted Accounting Pronouncement

Recently Adopted Accounting Pronouncement

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. The Company adopted ASU 2023-07 during the year ended December 31, 2024. See Note 11 Segment Reporting for further details.

 
New Accounting Pronouncements Not Yet Adopted

New Accounting Pronouncements Not Yet Adopted

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements and related disclosures.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive and Income - Expense Disaggregation Disclosures (Subtopic 220-40), requiring public business entities to provide disaggregated disclosures of relevant income statement expenses. The amendments aim to improve financial reporting by enhancing transparency in the notes to financial statements, specifically regarding expense categories. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is assessing the effect of this update on its consolidated financial statements and related disclosures.
v3.25.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Research and Development

 

         
   Year Ended 
   December 31, 
   2024   2023 
         
Amount Expensed for License, Strategic Alliance, and Research Agreements  $6,882,000   $5,993,000 
Schedule of Accounts Payable and Accrued Liabilities

 

   2024   2023 
         
Amount accrued and payable under License, Strategic Alliance, and Research Agreements  $1,725,000   $1,563,000 
           
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements  $490,000   $511,000 
v3.25.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2024
Leases  
Schedule of Balance Sheet Information Related to Leases

The following provides balance sheet information related to leases as of December 31, 2024 and 2023:

 

    2024     2023  
Assets                
Operating lease, right-of-use asset, net   $ 239,985     $ 228,295  
Liabilities                
Current portion of operating lease liabilities   $ 190,814     $ 172,975  
Operating lease liabilities, net of current portion     52,843       61,496  
Total operating lease liabilities   $ 243,657     $ 234,471  
Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases

At December 31, 2024, the future estimated minimum lease payments under non-cancelable operating leases are as follows:

 

     
2025  $205,315 
2026   54,744 
Total minimum lease payments   260,059 
Less amount representing interest   (16,402)
Present value of future minimum lease payments   243,657 
Less current portion of operating lease liabilities   (190,814)
Operating lease liabilities, net of current portion  $52,843 
Schedule of Reconciliation of Right-of-Use Assets and lease Liabilities

The following table provides a reconciliation for the Company’s right of use assets and lease liabilities:

 

   Right-of-Use Asset   Operating Lease Liability 
Balance at January 1, 2023  $47,687   $52,890 
Remeasurement of operating lease right-of-use assets and operating lease liability   198,847    198,847 
Operating right-of-use asset acquired through operating lease liability   141,989    141,989 
Amortizations   (160,228)   (159,255)
Balance at December 31, 2023   228,295    234,471 
Early termination of operating leases   (163,722)   (163,722)
Operating right-of-use asset acquired through operating lease liability   348,623    348,623 
Amortizations   (173,211)   (175,715)
Balance at December 31, 2024  $239,985   $243,657 
Schedule of Other Supplemental Information Related to Operating Leases

Other supplemental information related to operating leases is as follows:

 

         
  

As of

December 31,

 
   2024   2023 
Weighted average remaining term of operating leases (in years)   1.30    1.33 
Weighted average discount rate of operating leases   9.50%   7.36%
Schedule of Lease Expense

The components of lease expense were approximately as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
Operating lease cost  $191,000   $178,000 
Short-term lease cost   19,000    14,000 
Lease expense  $210,000   $192,000 
v3.25.1
Shareholders’ Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Stock Option Activity

A summary of stock option activity under the Plan during the years ended December 31, 2024 and 2023 is presented below:

 

   Options Outstanding   Options Exercisable 
  

Number of

Shares

  

Weighted-Average

Exercise Price

  

Number of

Options

  

Weighted-Average

Exercise Price

 
Outstanding December 31, 2022   1,037,591   $6.46    755,073   $5.87 
Granted   126,000    4.43           
Cancelled or expired   (72,395)   8.20           
Outstanding December 31, 2023   1,091,196    6.11    880,241    6.25 
Granted   259,000    4.56           
Cancelled or expired   (104,502)   6.90           
Outstanding December 31, 2024   1,245,694   $5.72    971,472   $6.07 
Schedule of Stock-based Compensation

Approximate stock-based compensation relating to options was as follows for the years ended December 31, 2024 and 2023:

 

   2024   2023 
General and administrative  $291,000   $566,000 
Research and development   361,000    451,000 
Stock-based compensation  $652,000   $1,017,000 
Schedule of Weighted Average Assumptions

For the years ended December 31, 2024 and 2023, the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following weighted average assumptions:

 

   2024   2023 
Term (in years)   5.58    5.73 
Risk Free Rate   4.15%   4.01%
Volatility   88.35%   86.91%
Dividend Yield   0.00%   0.00%
           
Grant Date Fair Value  $3.36   $3.25 
v3.25.1
Securities (Tables)
 12 Months Ended
Dec. 31, 2024
Cash and Cash Equivalents [Abstract]  
Schedule of Marketable of Securities

  

Amortized

Cost

  

Unrealized

Gains

  

Unrealized

Losses

  

Aggregate

Fair Value

 
Government and agency securities  $11,461,885   $3,270   $(1,670)  $11,463,485 
Corporate bonds   1,845,226    953    (944)   1,845,235 
Debt securities  $13,307,111   $4,223   $(2,614)   13,308,720 
Equity securities                  6,429,576 
                  $19,738,296 
                     
Included in cash and cash equivalents                 $3,236,312 
Included in marketable securities                 $16,501,984 

 

At December 31, 2023, the Company’s debt and equity securities consisted of the following:

 

  

Amortized

Cost

  

Unrealized

Gains

  

Unrealized

Losses

  

Aggregate

Fair Value

 
Government and agency securities  $5,576,819   $3,969   $(66,680)  $5,514,108 
Corporate bonds   8,322,723    514    (44,872)   8,278,365 
Debt securities  $13,899,542   $4,483   $(111,552)   13,792,473 
Equity securities                  15,825,016 
                  $29,617,489 
                     
Included in cash and cash equivalents                 $10,252,566 
Included in marketable securities                 $19,364,923 
Schedule of Contractual Maturities Investments of Marketable Securities

  

As of

December 31, 2024

 
Due within one year  $13,308,720 
Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities

The following table presents gross unrealized losses and fair values for those marketable debt securities that were in an unrealized loss position as of December 31, 2024, aggregated by investment category and the length of time that individual debt securities have been in a continuous loss position:

 

                 
   As of
December 31, 2024		 
   Less than 12 months   More than 12 months 
  

Fair

Value

  

Unrealized

Loss

  

Fair

Value

  

Unrealized

Loss

 
Government and agency securities  $1,284,465   $(64)  $797,324   $(1,606)
Corporate bonds   -    -    297,687    (944)
   $1,284,465   $(64)  $1,095,011   $(2,550)
v3.25.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets are Measured at Fair Value on Recurring Basis

                 
  

Fair Value Measurements as of

December 31, 2024

 
Description  Total   Level 1   Level 2   Level 3 
Government and agency securities  $11,463,485   $-   $11,463,485   $- 
Corporate bonds   1,845,235    -    1,845,235    - 
Money markets   694,420    694,420    -    - 
Mutual funds – fixed income   3,777,950    3,777,950    -    - 
Mutual funds – alternative investments   1,846,650    1,846,650    -    - 
Common stock   110,556    110,556    -    - 
Fair value recurring basis  $19,738,296   $6,429,576   $13,308,720   $- 
                     
Included in cash and cash equivalents  $3,236,312                
Included in marketable securities  $16,501,984                

 

                 
  

Fair Value Measurements as of

December 31, 2023

 
Description  Total   Level 1   Level 2   Level 3 
Government and agency securities  $5,514,108   $-   $5,514,108   $- 
Corporate bonds   8,278,365    -    8,278,365    - 
Money markets   10,252,566    10,252,566    -    - 
Mutual funds – fixed income   3,733,600    3,733,600    -    - 
Mutual funds – alternative investments   1,838,850    1,838,850    -    - 
Fair value recurring basis  $29,617,489   $15,825,016   $13,792,473   $- 
                     
Included in cash and cash equivalents  $10,252,566                
Included in marketable securities  $19,364,923                
v3.25.1
Loss Per Share of Common Shares (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share

 

         
  

For the year ended

December 31,

 
   2024   2023 
Warrants   70,000    177,998 
Stock options   1,245,694    1,091,196 
Anti-dilutive securities   1,315,694    1,269,194 
v3.25.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate

Our effective tax rate differs from the statutory federal tax rate as presented in the following table:

 

   2024   2023 
U.S. federal statutory tax rate   21%   21%
Permanent differences   4%   -%
Valuation allowance   (25)%   (21)%
           
Total:   -%   -%
Schedule of Deferred Tax Assets and Liabilities

The tax effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented below.

 

         
   December 31, 
   2024   2023 
Deferred tax assets          
Research and development credits  $2,222,625   $1,436,914 
Stock-based compensation   584,840    538,771 
Net operating loss carryforwards   9,353,936    7,383,777 
Unrealized losses on securities   -    22,624 
Research and development amortization   5,617,727    3,164,305 
Deferred tax asset   17,779,128    12,546,391 
           
Less: valuation allowance   (17,772,997)   (12,542,542)
Net deferred tax asset   6,131    3,849 
           
Deferred tax liabilities          
Unrealized gains on securities   (1,837)   - 
Operating lease right-of-use assets   (776)   - 
Fixed assets   (3,518)   (3,849)
Net deferred tax assets  $-   $- 
v3.25.1
Liquidity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net loss $ 20,781,213 $ 15,961,534
Working capital $ 20,916,000  
v3.25.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Cash and cash equivalents $ 6,619,000 $ 20,881,000
Prepaid expense and other current assets 1,234,566 2,038,653
Upfront payments for contractor fees, academic research studies and services, and subscriptions 820,000 746,000
Prepaid annual insurance fees 318,000 308,000
Interest receivable 97,000 860,000
Intellectual property related licensing and other fees   $ 125,000
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Cash FDIC insured amount $ 250,000  
v3.25.1
Schedule of Research and Development (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
License Strategic Alliance and Research Agreements [Member] | Research and Development Expense [Member]    
Loss Contingencies [Line Items]    
Amount Expensed for License, Strategic Alliance, and Research Agreements $ 6,882,000 $ 5,993,000
v3.25.1
Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements $ 1,234,566 $ 2,038,653
License Strategic Alliance and Research Agreements [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Amount accrued and payable under License, Strategic Alliance, and Research Agreements 1,725,000 1,563,000
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements $ 490,000 $ 511,000
v3.25.1
Commitments and Contingencies (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 23, 2021
Aug. 31, 2024
May 31, 2021
Jan. 31, 2018
Dec. 31, 2024
Dec. 31, 2023
Research and development expenses         $ 16,125,690 $ 11,894,315
Assignment Agreement [Member]            
Upfront payments         25,000  
BioNumerik Pharmaceuticals [Member] | Assignment Agreement [Member]            
Upfront payments       $ 25,000    
Commitments description       In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.    
AF Chemicals [Member] | AFC License Agreement [Member]            
Research and development expenses         125,000 175,000
Allarity Therapeuties [Member] | Asset Purchase Agreement [Member]            
Upfront payments $ 1,000,000          
Future payments $ 1,000,000          
Fortrea Inc [Member] | Fortrea Agreement [Member]            
Research and development expenses         5,487,000 2,096,000
Patheon API Services [Member] | Patheon Agreement [Member]            
Research and development expenses         18,000 4,000
Reduction in rsearch and development expenses         30,000 35,000
Piramal Pharma Solutions [Member] | Piramal Pharma Agreement [Member]            
Research and development expenses         130,000 49,000
Vivo Pharm [Member] | Vivo Pharm Agreement [Member]            
Research and development expenses         56,000 1,012,000
Translational Drug Development, LLC [Member]            
Research and development expenses         0 420,000
Berkshire Sterile Manufacturing [Member] | Berkshire Agreement [Member]            
Research and development expenses         141,000 334,000
Shilpa Medicare Limited [Member] | Shilpa Agreement [Member]            
Research and development expenses         827,000 1,313,000
Curia Global, Inc. [Member] | Curia Agreement [Member]            
Research and development expenses         82,000 414,000
LumaBridge, LLC [Member] | Luma Bridge Agreement [Member]            
Research and development expenses         0 $ 200,000
Actuate Therapeutics [Member] | Collaboration Agreement [Member]            
Actuate stock of restricted shares     25,000      
Nominal value acquired cost     $ 0      
Fair value         $ 111,000  
Actuate Therapeutics [Member] | Collaboration Agreement [Member] | Reverse Stock Split and IPO [Member]            
Number of shares hold   13,889        
v3.25.1
Schedule of Balance Sheet Information Related to Leases (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Leases      
Operating lease, right-of-use asset, net $ 239,985 $ 228,295 $ 47,687
Current portion of operating lease liabilities 190,814 172,975  
Operating lease liabilities, net of current portion 52,843 61,496  
Total operating lease liabilities $ 243,657 $ 234,471 $ 52,890
v3.25.1
Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Leases      
2025 $ 205,315    
2026 54,744    
Total minimum lease payments 260,059    
Less amount representing interest (16,402)    
Present value of future minimum lease payments 243,657 $ 234,471 $ 52,890
Less current portion of operating lease liabilities (190,814) (172,975)  
Operating lease liabilities, net of current portion $ 52,843 $ 61,496  
v3.25.1
Schedule of Reconciliation of Right-of-Use Assets and lease Liabilities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Leases    
Operating Right-of-Use Assets, Beginning Balance $ 228,295 $ 47,687
Operating Lease Liabilities, Beginning Balance 234,471 52,890
Operating Right-of-Use Assets, Remeasurement of operating lease right-of-use assets and operating lease liability   198,847
Operating Lease Liabilities, Remeasurement of operating lease right-of-use assets and operating lease liability   198,847
Operating Right-of-Use Assets, Operating right-of-use asset acquired through operating lease liability 348,623 141,989
Operating Lease Liabilities, Operating right-of-use asset acquired through operating lease liability 348,623 141,989
Operating Right-of-Use Assets, Amortizations (173,211) (160,228)
Operating Lease Liabilities, Amortizations (175,715) (159,255)
Operating Right-of-Use Assets, Early termination of Legacy West Leases (163,722)  
Operating Right-of-Use Assets, Early termination of Legacy West Leases (163,722)  
Operating Right-of-Use Assets, Ending Balance 239,985 228,295
Operating Lease Liabilities, Ending Balance $ 243,657 $ 234,471
v3.25.1
Schedule of Other Supplemental Information Related to Operating Leases (Details)
Dec. 31, 2024
Sep. 30, 2023
Leases    
Weighted average remaining term of operating leases (in years) 1 year 3 months 18 days 1 year 3 months 29 days
Weighted average discount rate of operating leases 9.50% 7.36%
v3.25.1
Schedule of Lease Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Leases    
Operating lease cost $ 191,000 $ 178,000
Short-term lease cost 19,000 14,000
Lease expense $ 210,000 $ 192,000
v3.25.1
Leases (Details Narrative) - USD ($)
 12 Months Ended
Sep. 01, 2024
May 01, 2024
Dec. 31, 2024
Dec. 31, 2023
Apr. 30, 2023
Leases          
New lease payments $ 6,800 $ 11,200      
Operating lease term         2 years
Cash used in operating activities associated with leases     $ 194,000 $ 177,000  
v3.25.1
Schedule of Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Equity [Abstract]    
Number of options outstanding, beginning balance 1,091,196 1,037,591
Weighted average exercise price per share, outstanding beginning $ 6.11 $ 6.46
Number of options exercisable, beginning valance 880,241 755,073
Number of options exercisable, weighted-average exercise price, beginning balance $ 6.25 $ 5.87
Number of shares, granted 259,000 126,000
Weighted average exercise price per share, granted $ 4.56 $ 4.43
Number of shares, cancelled or expired (104,502) (72,395)
Weighted average exercise price per share, cancelled or expired $ 6.90 $ 8.20
Number of shares, outstanding beinning 1,245,694 1,091,196
Weighted average exercise price per share, outstanding ending $ 5.72 $ 6.11
Number of options exercisable, ending balance 971,472 880,241
Number of options exercisable, weighted-average exercise price, ending balance $ 6.07 $ 6.25
v3.25.1
Schedule of Stock-based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Stock-based compensation $ 652,000 $ 1,017,000
General and Administrative Expense [Member]    
Stock-based compensation 291,000 566,000
Research and Development Expense [Member]    
Stock-based compensation $ 361,000 $ 451,000
v3.25.1
Schedule of Weighted Average Assumptions (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Equity [Abstract]    
Term (in years) 5 years 6 months 29 days 5 years 8 months 23 days
Risk Free Rate 4.15% 4.01%
Volatility 88.35% 86.91%
Dividend Yield 0.00% 0.00%
Grant Date Fair Value $ 3.36 $ 3.25
v3.25.1
Shareholders’ Equity (Details Narrative) - USD ($)
 12 Months Ended
Jun. 15, 2020
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]        
Preferred stock shares authorized   1,000,000 1,000,000  
Preferred stock, shares issued   0 0  
Preferred stock, shares outstanding   0 0  
Repurchase of shares value     $ 499,997  
Common stock, shares outstanding   10,784,725 10,721,192  
Common stock, shares authorized   25,000,000 25,000,000  
Common stock, shares issued   10,784,725 10,721,192  
Warrants to purchase shares of common stock   86,685    
Weighted average exercise price   $ 5.72 $ 6.11 $ 6.46
Exercise of warrants   $ 66,710  
Weighted average remaining contractual term of exercisable options   5 years 3 months 7 days    
Weighted average remaining contractual term of outstanding options   6 years 1 month 20 days    
Intrinsic value of options outstanding   $ 1,014,000 1,552,000  
Intrinsic value of options exercisable   1,014,000 1,526,000  
Unrecognized compensation expense   $ 908,000    
Weighted average period   1 year 6 months 14 days    
2018 Equity Incentive Plan [Member]        
Class of Stock [Line Items]        
Number of reserved shares   1,864,680    
Weighted average remaining contractual term of exercisable options   10 years    
Number of remain available shares   423,693    
General and Administrative Expense [Member]        
Class of Stock [Line Items]        
Restricted stock expense     $ 50,000  
Consultants [Member] | Restricted Stock [Member]        
Class of Stock [Line Items]        
Number of restricted shares   20,000 12,000  
Fair value of restricted shares   $ 81,000 $ 63,000  
Common stock, shares outstanding   0    
Consultants [Member] | 2024 Restricted Common Stock [Member]        
Class of Stock [Line Items]        
Common stock, shares outstanding     0  
Common Stock [Member]        
Class of Stock [Line Items]        
Repurchase of shares     145,348  
Repurchase of shares value     $ 15  
Number of restricted shares   20,000 12,000  
Restricted stock forfeited     2,500  
Number of shares issued   43,533    
Common Stock [Member] | Restricted Stock [Member]        
Class of Stock [Line Items]        
Number of restricted shares     9,500  
Warrant [Member]        
Class of Stock [Line Items]        
Warrants to purchase shares of common stock   70,000 177,998  
Weighted average exercise price   $ 18.75 $ 9.27  
Expiration date of warrants   Jun. 10, 2025    
Number of shares issued   21,313    
Exercise of warrants   $ 66,710    
Number of shares issued for cashless exercise of warrants   22,220    
Warrant [Member] | Minimum [Member]        
Class of Stock [Line Items]        
Expiration date of warrants     Mar. 07, 2024  
Warrant [Member] | Maximum [Member]        
Class of Stock [Line Items]        
Expiration date of warrants     Jun. 10, 2025  
Series A Preferred Stock [Member]        
Class of Stock [Line Items]        
Preferred stock shares authorized   1,000,000 1,000,000  
Preferred stock, shares issued   0 0  
Preferred stock, shares outstanding   0 0  
Series A Preferred Stock [Member] | IPO [Member]        
Class of Stock [Line Items]        
Conversion of Stock, Shares Converted 2,438,851      
v3.25.1
Schedule of Marketable of Securities (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Aggregate Fair Value $ 19,738,296 $ 29,617,489
Cash and Cash Equivalents [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Aggregate fair value 3,236,312 10,252,566
Marketable Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Aggregate fair value 16,501,984 19,364,923
US Government Debt Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Debt Securities, Available-for-Sale, Amortized Cost 11,461,885 5,576,819
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax 3,270 3,969
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax (1,670) (66,680)
Aggregate fair value 11,463,485 5,514,108
Corporate Debt Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Debt Securities, Available-for-Sale, Amortized Cost 1,845,226 8,322,723
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax 953 514
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax (944) (44,872)
Aggregate fair value 1,845,235 8,278,365
Debt Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Debt Securities, Available-for-Sale, Amortized Cost 13,307,111 13,899,542
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax 4,223 4,483
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax (2,614) (111,552)
Aggregate fair value 13,308,720 13,792,473
Equity Securities [Member]    
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]    
Aggregate fair value $ 6,429,576 $ 15,825,016
v3.25.1
Schedule of Contractual Maturities Investments of Marketable Securities (Details)
Dec. 31, 2024
USD ($)
Cash and Cash Equivalents [Abstract]  
Due within one year $ 13,308,720
v3.25.1
Schedule of Gross Unrealized Losses and Fair Values for Marketable Securities (Details)
Dec. 31, 2024
USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Fair Value Less than 12 months $ 1,284,465
Unrealized Loss Less than 12 months (64)
Fair Value More than 12 months 1,095,011
Unrealized Loss More than 12 months (2,550)
US Government Debt Securities [Member]  
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Fair Value Less than 12 months 1,284,465
Unrealized Loss Less than 12 months (64)
Fair Value More than 12 months 797,324
Unrealized Loss More than 12 months (1,606)
Corporate Debt Securities [Member]  
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Fair Value Less than 12 months
Unrealized Loss Less than 12 months
Fair Value More than 12 months 297,687
Unrealized Loss More than 12 months $ (944)
v3.25.1
Securities (Details Narrative) - Cash and Cash Equivalents [Member]
Dec. 31, 2024
USD ($)
Impairment Effects on Earnings Per Share [Line Items]  
Debt securities $ 2,542,000
Equity securities $ 2,542,000
v3.25.1
Schedule of Assets are Measured at Fair Value on Recurring Basis (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis $ 19,738,296 $ 29,617,489
Cash and Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 3,236,312 10,252,566
Marketable Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 16,501,984 19,364,923
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 6,429,576 15,825,016
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 13,308,720 13,792,473
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
US Government Agencies Short-Term Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 11,463,485 5,514,108
US Government Agencies Short-Term Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
US Government Agencies Short-Term Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 11,463,485 5,514,108
US Government Agencies Short-Term Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Corporate Bond Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 1,845,235 8,278,365
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 1,845,235 8,278,365
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 694,420 10,252,566
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 694,420 10,252,566
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Mutual Funds - Fixed Income [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 3,777,950 3,733,600
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 3,777,950 3,733,600
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Mutual Funds - Fixed Income [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Mutual Funds - Alternative Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 1,846,650 1,838,850
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 1,846,650 1,838,850
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Mutual Funds - Alternative Investments [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis
Common Stock [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 110,556  
Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis 110,556  
Common Stock [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis  
Common Stock [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value recurring basis  
v3.25.1
Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 1,315,694 1,269,194
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 70,000 177,998
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 1,245,694 1,091,196
v3.25.1
Schedule of Effective Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
U.S. federal statutory tax rate 21.00% 21.00%
Permanent differences 4.00%
Valuation allowance (25.00%) (21.00%)
Total:
v3.25.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets    
Research and development credits $ 2,222,625 $ 1,436,914
Stock-based compensation 584,840 538,771
Net operating loss carryforwards 9,353,936 7,383,777
Unrealized losses on securities 22,624
Research and development amortization 5,617,727 3,164,305
Deferred tax asset 17,779,128 12,546,391
Less: valuation allowance (17,772,997) (12,542,542)
Net deferred tax asset 6,131 3,849
Deferred tax liabilities    
Unrealized gains on securities (1,837)
Operating lease right-of-use assets (776)
Fixed assets (3,518) (3,849)
Net deferred tax assets
v3.25.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards for federal income tax $ 43,600,000 $ 34,500,000
Net operating loss carryforwards, description The NOL carryforwards generated prior to 2018 of approximately $3,100,000 could expire over time beginning in 2035, if not used. The NOL carryforwards generated from January 1, 2018 through December 31, 2024 of approximately $40,500,000 do not expire and are carried forward indefinitely.  
Net operating loss carryforwards, state $ 1,000,000  
Net operating loss carryforwards, foreign 500,000  
Research and development tax credit carryforwards 2,200,000  
Gross deferred tax asset $ 5,617,727 $ 3,164,305
v3.25.1
Segment Reporting (Details Narrative)
 12 Months Ended
Dec. 31, 2024
USD ($)
Segment
Dec. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of operating segment | Segment 1  
Manufacturing costs | $ $ 11,400,000 $ 8,453,000